Pfizer Ltd Share Price
As on 18 November 2025 at 23:48 IST
Pfizer Q1 FY26 Results:
Net profit for the period increased 27.3% to ₹191.8 crores in Q1 FY26, from ₹150.7 crores in Q1 FY25. Total income for the quarter increased 10.8% year-on-year to ₹670.2 crores from ₹604.7 crores.
About Pfizer Ltd
Pfizer Ltd. is a leading pharmaceutical company in India. It is engaged in the development, manufacturing, and marketing of a wide range of pharmaceutical products. The company was founded in 1950. Pfizer has grown to become a significant player in the Indian pharmaceutical industry. The headquarters of the company is located in Mumbai, Maharashtra. Pfizer's main products include Lipitor (atorvastatin), Prevenar 13 (pneumococcal conjugate vaccine), and Eliquis (apixaban). The company also offers medicines for various therapeutic areas. This includes cardiovascular, pain management, and women's health. Pfizer falls under the pharmaceutical and biotechnology sector. +
The Current prices are delayed, log in for live prices
LOGINOver 1 Month
-5.46%
Over 6 Months
13.28%
Over 1 Year
-2.40%
Over 3 Years
12.57%
Pfizer Ltd Summary
Close ₹5,061.50
Open ₹5,074.50
High ₹5,089
Low ₹5,048
Volume 6,836
Net Turnover (in Cr) ₹3.46
52Wk High ₹5,993
52Wk Low ₹3,701
52Wk High / Low
3,701
5,993
Pfizer Ltd Fundamentals
Key Financial Data
Market Cap (in Cr) ₹23,155.21
EPS (TTM) 154.48
Book Value (BV) 841.20
Div. Yield 3.26 %
P/E (TTM) 27.57
Price/Book Value 6.01
Delivery % 55.66 %
Face Value 10
Key Ratios
PE Ratio 23.86
PB Ratio 4.34
EV to Sales 6.82
PEG Ratio 0.61
ROA 17.52
ROE 16.40
Debt-Equity 0.01
Net Profit Margin 28.09
Operating Profit Margin 40.07
Pfizer Ltd Financials
Profit and Loss
No data available
Balance Sheet
No data available
Cash Flow
| Particulars (in ₹ Cr.) | FY 2008 | FY 2007 | FY 2006 | FY 2005 | FY 2004 |
|---|---|---|---|---|---|
| Net Cash From Operating Activities | 237.76 | 16.63 | 123.19 | 102.74 | 87.21 |
| Net Cash Used In Investing Activities | -78.87 | 232.35 | 7.46 | -73.08 | -68.03 |
| Net Cash Used In Financing Activities | -95.20 | -75.89 | -33.82 | -46.02 | -14.71 |
Profit and Loss
| Particulars (in ₹ Cr.) | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Total Revenue | 2,453.60 | 2,373.68 | 2,525.81 | 2,673.64 | 2,319.67 |
| Total Expenses | 1,610.32 | 1,635.56 | 1,734.80 | 1,900.75 | 1,650.95 |
| Profit Before Tax | 1,016.09 | 746.07 | 824.01 | 772.89 | 668.72 |
| Profit After Tax | 767.60 | 551.33 | 623.93 | 612.56 | 497.61 |
| Operating Profit After Depreciation | 851.69 | 753.53 | 804.40 | 783.38 | 683.83 |
Balance Sheet
| Particulars (in ₹ Cr.) | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Fixed Assets | 723.62 | 712.71 | 749.25 | 840.96 | 864.74 |
| Total Non Current Assets | 1,398.26 | 1,490.97 | 1,507.39 | 1,504.03 | 1,341.19 |
| Total Current Assets | 3,512.85 | 2,737.81 | 2,493.34 | 2,396.48 | 1,924.71 |
| Total Assets | 4,911.11 | 4,228.78 | 4,000.73 | 3,900.51 | 3,265.90 |
| Total Shareholder's Fund | 4,217.41 | 3,595.54 | 3,207.30 | 2,864.41 | 2,393.04 |
Cash Flow
| Particulars (in ₹ Cr.) | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Net Cash From Operating Activities | 659.75 | 256.84 | 355.68 | 667.08 | 427.33 |
| Net Cash Used In Investing Activities | -71.34 | 53.70 | -36.05 | -575.02 | -468.84 |
| Net Cash Used In Financing Activities | -205.34 | -235.14 | -345.79 | -180.51 | -1,571.07 |
No data available
| Particulars (in ₹ Cr.) | 2025-09 | 2025-06 | 2025-03 | 2024-12 | 2024-09 |
|---|---|---|---|---|---|
| Total Revenue | 642.34 | 603.05 | 591.91 | 537.99 | 588.59 |
| Total Expenses | 412.41 | 393.03 | 364.41 | 392 | 399.34 |
| Profit Before Tax | 255.37 | 259.53 | 425.80 | 172.44 | 215.23 |
| Profit After Tax | 189.02 | 191.75 | 330.94 | 127.60 | 158.35 |
| Operating Profit after Depreciation | 271.78 | 277.19 | 272.08 | 188.75 | 232.32 |
Pfizer Ltd Technicals
Support and Resistance
S3 S2 S1 Pivot R1 R2 R3
S1 5,043.33
S2 5,025.17
S3 5,002.33
Pivot 5,066.17
R1 5,084.33
R2 5,107.17
R3 5,125.33
Moving Average
20 SMA 5,191.75
50 SMA 5,177.51
100 SMA 5,286.18
200 SMA 4,915.71
Pfizer Ltd Corporate Actions
Pfizer Ltd
₹30.0/Share
Announcement Date 09 Jul 2025
Record Date 09 Jul 2025
Div Yield 300%
Pfizer Ltd Peer Comparison
| Company | Price | Market Cap (in Cr) |
|---|---|---|
| Sun Pharmaceutical Industries Ltd | ₹1,763.70 | ₹4,23,170.71 |
| Divis Laboratories Ltd | ₹6,523.25 | ₹1,73,171.79 |
| Torrent Pharmaceuticals Ltd | ₹3,816.75 | ₹1,29,170.36 |
| Cipla Ltd | ₹1,536.25 | ₹1,24,093.85 |
| Dr Reddys Laboratories Ltd | ₹1,244.50 | ₹1,03,868.61 |
Pfizer Ltd Top Mutal Funds Invested
| Fund Name | AUM |
|---|---|
| DSP Healthcare Fund | 3.32% |
| SBI Innovative Opportunities Fund | 3.23% |
| Nippon India Pharma Fund | 1.99% |
| Quant Small Cap Fund | 1.49% |
| ICICI Pru P.H.D Fund | 1.46% |
Pfizer Ltd News
Pfizer gains after Q2 PAT rises 19% YoY
Pfizer rose 2.48% to Rs 5,144.75 after the company posted a decent performance in the quarter ended September 2025.
13 Nov 2025, 10:40 am
Pfizer schedules board meeting
On 12 November 2025
04 Nov 2025, 12:55 pm
Volumes jump at Pfizer Ltd counter
Pfizer Ltd witnessed volume of 3.35 lakh shares by 14:14 IST on NSE, a 22.25 times surge over two-week average daily volume of 15039 shares
01 Oct 2025, 02:30 pm
Volumes soar at Pfizer Ltd counter
Pfizer Ltd clocked volume of 3.71 lakh shares by 14:14 IST on NSE, a 20.89 times surge over two-week average daily volume of 17752 shares
14 Aug 2025, 02:30 pm
Pfizer jumps after robust Q1 earnings
Pfizer climbed 5.16% to Rs 5,390.30 after posting a strong performance in the June quarter.
14 Aug 2025, 10:09 am
Pfizer Ltd Stock Analysis
- Annual revenue for Pfizer Ltd increased by 3.37% to ₹2,453.60 crore in FY 2025 from ₹2,373.68 crore in FY 2024.
- Annual Net Profit for Pfizer Ltd increased by 39.23% to ₹767.60 crore in FY 2025 from ₹551.33 crore in FY 2024.
- Promoter Shareholding in Pfizer Ltd remains unchanged by 0.00% in the most recent quarter, from 63.92% in June 2025 to 63.92% in September 2025.
- Pfizer Ltd delivered a 1-year return of -2.40% compared to the Nifty 50, which provided a return of 10.91% as of the last trading session.
- Pfizer Ltd share price moved up by 0.21% from its previous close of INR ₹5,061.50. The latest Pfizer Ltd share price is INR ₹5,072.
- Pfizer Ltd share price today has been at a low of 5,047 and a high of 5,084. Over the past 52 weeks, the Pfizer Ltd share price has seen a low of 3,701 and a high of 5,993.
About Pfizer Ltd
Pfizer Ltd. is a prominent Indian pharmaceutical company. It is headquartered in Mumbai, Maharashtra. The company was initiated in 1950 and has established itself as a key player in India's pharmaceutical and biotechnology sector. This is achieved through its commitment to developing, manufacturing, and marketing high-quality medicines and vaccines.
The company's operations span multiple therapeutic areas. This includes immunology, oncology, cardiology, endocrinology, and neurology. With decades of experience, Pfizer Ltd. has built a reputation for its dedication to research and development. This resulted in an extensive product portfolio aimed at improving patient health and well-being.
The company maintains strong ties with its global parent, Pfizer Inc., based in New York City. The promoter shareholding of the company stands at 63.92%. Pfizer East India BV controls the major share at 39.75%. This demonstrates the promoter's strong commitment to the business's growth and success in the Indian pharmaceutical market.
Pfizer Ltd.'s main products include a wide range of pharmaceutical drugs and vaccines. Some of the key products in its portfolio are Lipitor (atorvastatin), Prevenar 13 (pneumococcal conjugate vaccine), and Eliquis (apixaban). The company also offers medicines for various therapeutic areas. This includes cardiovascular, anti-infectives, pain management, and women's health.
Pfizer Ltd. is one of the top pharmaceutical companies in India, with a strong market presence and a reputation for excellence. The company's solid capabilities and extensive product portfolio have positioned it as a key player in the industry. It may not be the largest by market capitalization. However, Pfizer Ltd.'s strong market position and reputation for quality have solidified its status as a trusted and reliable pharmaceutical provider.
The registered office of Pfizer Ltd. is located at The Capital, 1802 / 1901, G Block, Bandra Kurla Complex, Bandra (East), Mumbai - 400051, Maharashtra, India. Its registrar & transfer agent is KFin Technologies Private Limited. The managerial promoters of the company include:
Economic Impact Pfizer Ltd. has had a substantial economic impact on the Indian pharmaceutical sector. The company has facilitated access to quality healthcare for millions of individuals and families by providing a wide range of medicines and vaccines. The availability of innovative pharmaceutical products has enabled individuals to receive timely and effective medical treatment. This contributes to improved health outcomes and overall well-being. Also, this has contributed to economic stability and growth in the regions where Pfizer Ltd. operates.
Healthcare Advancements One of the significant influences of Pfizer Ltd. is its role in advancing healthcare in India. The company invests heavily in research and development to discover and develop new medicines and vaccines that address unmet medical needs. Pfizer Ltd.'s commitment to innovation has resulted in the introduction of breakthrough therapies in various therapeutic areas. This includes oncology, cardiology, and immunology. These advancements have improved the quality of life for patients and have set new standards in the healthcare industry.
Patient-Centric Approach Pfizer Ltd.'s patient-centric approach has set new standards in the pharmaceutical industry. The company focuses on understanding and meeting the specific needs of its patients. This ensures that they receive personalized and comprehensive medical care. Pfizer Ltd.'s commitment to patient satisfaction has resulted in high patient retention rates and long-term relationships with healthcare providers. The company's emphasis on patient-centricity has encouraged other players in the industry to adopt similar practices.
Innovation and Technological Advancements Pfizer Ltd. is at the forefront of innovation and technological advancements in the pharmaceutical sector. The company leverages advanced technologies such as digital health platforms and artificial intelligence. This technology enhances its operations and improves patient experience. By embracing technology, Pfizer Ltd. has improved its operational efficiency, reduced treatment times, and provided innovative medical solutions to its patients. These technological advancements have positioned Pfizer Ltd. as a leader in the pharmaceutical industry.
Corporate Social Responsibility Pfizer Ltd. is committed to corporate social responsibility (CSR). Also, it undertakes various initiatives to support community development. The company's CSR activities focus on education, healthcare, and environmental sustainability. By investing in these areas, Pfizer Ltd. has made a positive impact on the lives of many individuals and communities. This fosters social and economic development.
Pfizer Ltd. has made a significant impact on the Indian pharmaceutical sector and the economy. Pfizer Ltd.'s focus on corporate social responsibility has further enhanced its influence and reputation. As the company continues to evolve and expand its operations, it remains dedicated to driving healthcare excellence and improving the quality of life for its patients and communities.
The company's operations span multiple therapeutic areas. This includes immunology, oncology, cardiology, endocrinology, and neurology. With decades of experience, Pfizer Ltd. has built a reputation for its dedication to research and development. This resulted in an extensive product portfolio aimed at improving patient health and well-being.
The company maintains strong ties with its global parent, Pfizer Inc., based in New York City. The promoter shareholding of the company stands at 63.92%. Pfizer East India BV controls the major share at 39.75%. This demonstrates the promoter's strong commitment to the business's growth and success in the Indian pharmaceutical market.
Pfizer Ltd.'s main products include a wide range of pharmaceutical drugs and vaccines. Some of the key products in its portfolio are Lipitor (atorvastatin), Prevenar 13 (pneumococcal conjugate vaccine), and Eliquis (apixaban). The company also offers medicines for various therapeutic areas. This includes cardiovascular, anti-infectives, pain management, and women's health.
Pfizer Ltd. is one of the top pharmaceutical companies in India, with a strong market presence and a reputation for excellence. The company's solid capabilities and extensive product portfolio have positioned it as a key player in the industry. It may not be the largest by market capitalization. However, Pfizer Ltd.'s strong market position and reputation for quality have solidified its status as a trusted and reliable pharmaceutical provider.
The registered office of Pfizer Ltd. is located at The Capital, 1802 / 1901, G Block, Bandra Kurla Complex, Bandra (East), Mumbai - 400051, Maharashtra, India. Its registrar & transfer agent is KFin Technologies Private Limited. The managerial promoters of the company include:
- Pradip Shah
- Meenakshi Nevatia
- P Rengan
- Amit Agarwal
- Sunil Lalbhai
Impact of the Company
Pfizer Ltd. is a prominent pharmaceutical company in India. It engaged in the development, manufacturing, and marketing of a wide range of pharmaceutical products. The company focuses on providing innovative and high-quality medicines and vaccines to improve patient health and well-being. Pfizer Ltd. operates in various therapeutic areas, including immunology, oncology, cardiology, endocrinology, and neurology.Economic Impact Pfizer Ltd. has had a substantial economic impact on the Indian pharmaceutical sector. The company has facilitated access to quality healthcare for millions of individuals and families by providing a wide range of medicines and vaccines. The availability of innovative pharmaceutical products has enabled individuals to receive timely and effective medical treatment. This contributes to improved health outcomes and overall well-being. Also, this has contributed to economic stability and growth in the regions where Pfizer Ltd. operates.
Healthcare Advancements One of the significant influences of Pfizer Ltd. is its role in advancing healthcare in India. The company invests heavily in research and development to discover and develop new medicines and vaccines that address unmet medical needs. Pfizer Ltd.'s commitment to innovation has resulted in the introduction of breakthrough therapies in various therapeutic areas. This includes oncology, cardiology, and immunology. These advancements have improved the quality of life for patients and have set new standards in the healthcare industry.
Patient-Centric Approach Pfizer Ltd.'s patient-centric approach has set new standards in the pharmaceutical industry. The company focuses on understanding and meeting the specific needs of its patients. This ensures that they receive personalized and comprehensive medical care. Pfizer Ltd.'s commitment to patient satisfaction has resulted in high patient retention rates and long-term relationships with healthcare providers. The company's emphasis on patient-centricity has encouraged other players in the industry to adopt similar practices.
Innovation and Technological Advancements Pfizer Ltd. is at the forefront of innovation and technological advancements in the pharmaceutical sector. The company leverages advanced technologies such as digital health platforms and artificial intelligence. This technology enhances its operations and improves patient experience. By embracing technology, Pfizer Ltd. has improved its operational efficiency, reduced treatment times, and provided innovative medical solutions to its patients. These technological advancements have positioned Pfizer Ltd. as a leader in the pharmaceutical industry.
Corporate Social Responsibility Pfizer Ltd. is committed to corporate social responsibility (CSR). Also, it undertakes various initiatives to support community development. The company's CSR activities focus on education, healthcare, and environmental sustainability. By investing in these areas, Pfizer Ltd. has made a positive impact on the lives of many individuals and communities. This fosters social and economic development.
Pfizer Ltd. has made a significant impact on the Indian pharmaceutical sector and the economy. Pfizer Ltd.'s focus on corporate social responsibility has further enhanced its influence and reputation. As the company continues to evolve and expand its operations, it remains dedicated to driving healthcare excellence and improving the quality of life for its patients and communities.
FAQ’s
What is the share price of Pfizer Ltd today?
Pfizer Ltd share price as on 18 Nov 2025 is ₹ 5072.0
What is the Market Cap of Pfizer Ltd?
The market cap of Pfizer Ltd stock is ₹23,155.21 Cr.
What is the PE Ratio of Pfizer Ltd?
The Price to Earnings (P/E) Ratio of Pfizer Ltd is 23.86
What is the PB Ratio of Pfizer Ltd?
The Price to Book (P/B) Ratio of Pfizer Ltd is 4.34
What is the 52 week high of Pfizer Ltd Share Price?
The 52 week high of Pfizer Ltd share price stands at ₹5,993
What is the 52 week low of Pfizer Ltd Share Price?
The 52 week low of Pfizer Ltd share price stands at ₹3,701
How can I buy shares of Pfizer Ltd?
Simply open a demat account with Torus Digital and place an order to buy shares of Pfizer Ltd.
Open FREE
3-in-1 Account
for all your banking, trading and demat needs
Trade in stocks,
derivatives and F&O
